EGFR and neoplasm: Epidermal growth factor receptor protein expression is no longer considered as selection criteria for cetuximab sensitivity (Cunningham et al, 2004; Saltz et al, 2004; Chung et al, 2005), and the mechanism of cetuximab's anti-tumour activity remains a fundamental question to be clearly addressed.